Telix Pharmaceuticals is trading 4.3% down today at $11.05 as a broader healthcare sector decline weighs on sentiment, overshadowing the company's latest infrastructure milestone.
- The company officially opened a multi-million-dollar radiopharmaceutical research and manufacturing facility in Melbourne today, aimed at accelerating the development of new cancer treatments.
- Despite the constructive fundamental update and pipeline progress, the stock is giving back recent gains as industry-wide selling pressure impacts the share price.